secwatch.observer — SEC 8-K summary
======================================

Issuer:     CNBX Pharmaceuticals Inc. (CNBX)
CIK:        0001343009
Form:       8-K
Filed at:   2021-07-06T23:59:59+00:00
Accession:  0001683168-21-002832
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dr. Inbar Maymon Pomeranchik appointed as independent board member of Cannabics Pharmaceuticals
--------------------------------------------------------------------------------

- Dr. Inbar Maymon-Pomeranchik, 43, appointed to board effective July 1, 2021.
- Holds a PhD in molecular biology from Hebrew University, postdoc from Weizmann Institute, with 20 years exec experience in biotech and global medical cannabis.
- Currently serves as founder & CEO of AgChimedes Group, founder of BioDiligence, Executive Director of Ananda Developments, Director of NRGene, and Advisory Board member of Avida Global.
- Appointment was unanimously approved by the Board of Directors on July 1, 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1343009/000168316821002832/0001683168-21-002832-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1343009/000168316821002832/cannabics_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-21-002832

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer